Oxford Biodynamics PLC Total Liabilities
Oxford Biodynamics PLC total liabilities. Based on the latest financial reports, Oxford Biodynamics PLC (OBD) has total liabilities worth GBX5.84 Million GBX (≈ $710.32 USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Oxford Biodynamics PLC to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Oxford Biodynamics PLC (2013–2025)
Total liabilities of Oxford Biodynamics PLC from 2013 to 2025. This chart illustrates how Oxford Biodynamics PLC's total liabilities have evolved over time, based on quarterly financial data. Explore Oxford Biodynamics PLC (OBD) long-term investment share to see how much of total assets are deployed in long-term investments.
Oxford Biodynamics PLC Competitors by Total Liabilities
The table below lists competitors of Oxford Biodynamics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Delta Electronics (Thailand) Public Company Limited
F:DLS
|
Germany | €86.52 Billion |
|
Selina Hospitality PLC
NASDAQ:SLNAF
|
USA | $809.06 Million |
|
Image Scan Holdings Plc
LSE:IGE
|
UK | GBX487.00K |
|
Northann Corp.
NYSE MKT:NCLX
|
USA | $12.34 Million |
|
Sporttotal AG
F:WIG1
|
Germany | €50.80 Million |
|
ECR Minerals plc
LSE:ECR
|
UK | GBX81.15K |
|
JAYDEN RESOURCES INC.
F:977
|
Germany | €1.11 Million |
|
Bangkok Bank Public Company Limited
F:BKKF
|
Germany | €4.03 Trillion |
Liability Composition Analysis (2013–2025)
This chart breaks down Oxford Biodynamics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Oxford Biodynamics PLC asset portfolio.
Liquidity & Leverage Metrics
Oxford Biodynamics PLC Total Liabilities Ratios Explained
Oxford Biodynamics PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oxford Biodynamics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oxford Biodynamics PLC (2013–2025)
The table below shows the annual total liabilities of Oxford Biodynamics PLC from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | GBX6.97 Million ≈ $848.05 |
-10.06% |
| 2024-09-30 | GBX7.75 Million ≈ $942.95 |
-23.05% |
| 2023-09-30 | GBX10.07 Million ≈ $1.23K |
+15.03% |
| 2022-09-30 | GBX8.76 Million ≈ $1.07K |
+0.81% |
| 2021-09-30 | GBX8.69 Million ≈ $1.06K |
+390.18% |
| 2020-09-30 | GBX1.77 Million ≈ $215.60 |
+47.91% |
| 2019-09-30 | GBX1.20 Million ≈ $145.76 |
+34.30% |
| 2018-09-30 | GBX892.00K ≈ $108.53 |
-17.71% |
| 2017-09-30 | GBX1.08 Million ≈ $131.89 |
-15.11% |
| 2016-09-30 | GBX1.28 Million ≈ $155.37 |
+82.95% |
| 2015-09-30 | GBX698.00K ≈ $84.93 |
-26.37% |
| 2014-09-30 | GBX948.00K ≈ $115.34 |
+43.64% |
| 2013-09-30 | GBX660.00K ≈ $80.30 |
-- |
About Oxford Biodynamics PLC
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more